Tositumomab: Difference between revisions
Jump to navigation
Jump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 19: | Line 19: | ||
! Tositumomab | ! Tositumomab | ||
! 167000 | ! 167000 | ||
! | ! 205800 | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
| Line 37: | Line 37: | ||
! 64.8 | ! 64.8 | ||
! 68 | ! 68 | ||
! | ! 206 | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
| Line 49: | Line 49: | ||
! .078 | ! .078 | ||
! .017 | ! .017 | ||
! | ! .009 | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
| Line 58: | Line 58: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! Dosage | ! Dosage | ||
! Tositumomab | ! Tositumomab | ||
! 500 (4th Infusion) | ! 500 mg (4th Infusion) | ||
! | ! 325 mg/m<sup>2</sup> (4th Infusion) | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
Revision as of 10:16, 6 December 2010
PharmacokineticsPharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics [1] | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | 7.6 | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | 167000 | 205800 | Ibritumomab |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Protein Binding (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | 64.8 | 68 | 206 | Ibritumomab |
| AUC (ng/ml/hr) | Tositumomab | 32939000 | Rituximab | Ibritumomab |
| Clearance (L/h) | .078 | .017 | .009 | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage | Tositumomab | 500 mg (4th Infusion) | 325 mg/m2 (4th Infusion) | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |